Nidhi S. Mundada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nidhi S. Mundada has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Emily McGrew
Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publicationsNiyousha Sadeghpour
Department of Radiology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publications- Renaud La Joie
Edward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco
4 shared publications Sandhitsu R. Das
Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publications- Daniel R. Schonhaut
Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania
3 shared publications - Gil Dan Rabinovici
Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, USA
3 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71571
Vulnerability of anterior medial temporal lobe subregions to early tau‐related neurodegeneration in Alzheimer's disease: Converging evidence from tau‐PET and plasma p‐tau217
INTRODUCTION: The anterior medial temporal lobe (MTL), including the entorhinal cortex (ERC) and Brodmann area 35 (BA35), is among the earliest cortical sites of tau pathology in Alzheimer's disease (AD), yet conventional image segmentation methods poorly capture these regions. METHODS: We applied an automated segmentation approach using an extended Automatic Segmentation of Hippocampal Subfields (ASHS) atlas, including anterior MTL subregions, in 448 Pennsylvania Alzheimer's Disease Research Center participants with magnetic resonance imaging, tau positron emission tomography (PET) ( n = 199), and/or plasma phosphorylated tau 217 (p‐tau217) ( n = 377). Amyloid beta (Aβ) positivity was defined using PET or plasma. RESULTS: Tau‐PET showed an anterior–posterior gradient, with highest uptake in BA35, ERC, and anterior hippocampus. Increased MTL tau‐PET uptake and plasma p‐tau217 were associated with cortical thinning localized to BA35 and ERC, even in cognitively unimpaired Aβ‐positive individuals. CONCLUSIONS: Anterior MTL subregions, especially BA35, show early vulnerability to tau‐related neurodegeneration. Extended anterior MTL parcellation improves localization of early tau‐associated structural changes and may facilitate biological staging in preclinical AD.
- 17 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71571
Open AccessVulnerability of anterior medial temporal lobe subregions to early tau‐related neurodegeneration in Alzheimer's disease: Converging evidence from tau‐PET and plasma p‐tau217
INTRODUCTION: The anterior medial temporal lobe (MTL), including the entorhinal cortex (ERC) and Brodmann area 35 (BA35), is among the earliest cortical sites of tau pathology in Alzheimer's disease (AD), yet conventional image segmentation methods poorly capture these regions. METHODS: We applied an automated segmentation approach using an extended Automatic Segmentation of Hippocampal Subfields (ASHS) atlas, including anterior MTL subregions, in 448 Pennsylvania Alzheimer's Disease Research Center participants with magnetic resonance imaging, tau positron emission tomography (PET) ( n = 199), and/or plasma phosphorylated tau 217 (p‐tau217) ( n = 377). Amyloid beta (Aβ) positivity was defined using PET or plasma. RESULTS: Tau‐PET showed an anterior–posterior gradient, with highest uptake in BA35, ERC, and anterior hippocampus. Increased MTL tau‐PET uptake and plasma p‐tau217 were associated with cortical thinning localized to BA35 and ERC, even in cognitively unimpaired Aβ‐positive individuals. CONCLUSIONS: Anterior MTL subregions, especially BA35, show early vulnerability to tau‐related neurodegeneration. Extended anterior MTL parcellation improves localization of early tau‐associated structural changes and may facilitate biological staging in preclinical AD.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S8) , e110000
Enrichment of patients with concomitant LATE on the Alzheimer’s disease continuum: comparing structural and cognitive trajectories
Background: Overlap in clinical presentations, absence of well‐validated in‐vivo biomarkers for Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE), and frequent co‐occurrence with AD, complicates identifying mixed AD/LATE cases. Autopsy studies suggest greater hippocampal atrophy in AD patients with concomitant LATE. We aimed to identify patients along the AD continuum enriched for LATE by defining the lower quartile of hippocampal volume (HV) as a biomarker for possible LATE and explore atrophy patterns and cognitive profiles. Method: 164 cognitively impaired participants from ADNI with T1‐MRI and amyloid‐ and tau‐PET within 365 days were grouped based on HV quartiles (adjusted for age/intracranial volume) and amyloid status into suspected 1) AD‐only (HV>50th‐percentile, amyloid‐positive), 2) LATE‐only (HV<25th‐percentile, amyloid‐negative), 3) AD+LATE (HVFigure‐2B(II)). AD+LATE showed faster atrophy than AD, however, the effect weakened when controlling for tau (Figure‐2B(IV‐V). Cross‐sectionally, LATE‐only and AD+LATE group showed lower memory and language scores than AD‐only, even after controlling for tau (Figure‐3A); however, longitudinally, AD+LATE declined faster across all domains, differing from AD‐only when controlling for tau, suggesting a more aggressive disease (Figure 3B). Conclusion: Patients in lower quartile of HV on the AD continuum exhibit LATE‐like patterns, suggesting underlying LATE pathology. A simple HV percentile‐based metric may help identify patients with concomitant LATE and AD with potential relevance for clinical trials and anti‐amyloid therapies.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S8) , e110000
Open AccessEnrichment of patients with concomitant LATE on the Alzheimer’s disease continuum: comparing structural and cognitive trajectories
Background: Overlap in clinical presentations, absence of well‐validated in‐vivo biomarkers for Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE), and frequent co‐occurrence with AD, complicates identifying mixed AD/LATE cases. Autopsy studies suggest greater hippocampal atrophy in AD patients with concomitant LATE. We aimed to identify patients along the AD continuum enriched for LATE by defining the lower quartile of hippocampal volume (HV) as a biomarker for possible LATE and explore atrophy patterns and cognitive profiles. Method: 164 cognitively impaired participants from ADNI with T1‐MRI and amyloid‐ and tau‐PET within 365 days were grouped based on HV quartiles (adjusted for age/intracranial volume) and amyloid status into suspected 1) AD‐only (HV>50th‐percentile, amyloid‐positive), 2) LATE‐only (HV<25th‐percentile, amyloid‐negative), 3) AD+LATE (HVFigure‐2B(II)). AD+LATE showed faster atrophy than AD, however, the effect weakened when controlling for tau (Figure‐2B(IV‐V). Cross‐sectionally, LATE‐only and AD+LATE group showed lower memory and language scores than AD‐only, even after controlling for tau (Figure‐3A); however, longitudinally, AD+LATE declined faster across all domains, differing from AD‐only when controlling for tau, suggesting a more aggressive disease (Figure 3B). Conclusion: Patients in lower quartile of HV on the AD continuum exhibit LATE‐like patterns, suggesting underlying LATE pathology. A simple HV percentile‐based metric may help identify patients with concomitant LATE and AD with potential relevance for clinical trials and anti‐amyloid therapies.
- Open Access
- 13 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (12) , e70970
Enrichment of patients with concomitant limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) on the Alzheimer's disease continuum using hippocampal volume
INTRODUCTION: Clinical overlap between Alzheimer's disease (AD) and limbic‐predominant age‐related transactive response DNA binding protein 43 (TDP‐43) encephalopathy (LATE), combined with the absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut‐off and examined associated atrophy and cognitive profiles. METHODS: We studied cognitively impaired (CI) Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with T1‐magnetic resonance imaging (MRI) and amyloid‐ and tau‐positron emission tomography (PET). Participants were classified into suspected (s) AD+sLATE−, AD−sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole‐brain atrophy patterns and cognitive profiles were compared cross‐sectionally and longitudinally. Classification was validated in an autopsy cohort. RESULTS: AD+sLATE+ showed greater anterior hippocampal (AH) and amygdala atrophy than AD+sLATE−. AD−sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. DISCUSSION: A simple HV quartile cut‐off may help identify mixed AD/LATE pathology and support clinical trial enrichment. Highlights: Quartiles of HVs stratify CI individuals. Approach distinguishes suspected AD+sLATE–, AD–sLATE+, and AD+sLATE+ subgroups. The method is simple, scalable, and requires no complex modeling or biomarker panels. It enables practical identification of mixed pathology in clinical settings. It supports trial enrichment by excluding or targeting mixed pathology cases.
- 13 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (12) , e70970
Open AccessEnrichment of patients with concomitant limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) on the Alzheimer's disease continuum using hippocampal volume
INTRODUCTION: Clinical overlap between Alzheimer's disease (AD) and limbic‐predominant age‐related transactive response DNA binding protein 43 (TDP‐43) encephalopathy (LATE), combined with the absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut‐off and examined associated atrophy and cognitive profiles. METHODS: We studied cognitively impaired (CI) Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with T1‐magnetic resonance imaging (MRI) and amyloid‐ and tau‐positron emission tomography (PET). Participants were classified into suspected (s) AD+sLATE−, AD−sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole‐brain atrophy patterns and cognitive profiles were compared cross‐sectionally and longitudinally. Classification was validated in an autopsy cohort. RESULTS: AD+sLATE+ showed greater anterior hippocampal (AH) and amygdala atrophy than AD+sLATE−. AD−sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. DISCUSSION: A simple HV quartile cut‐off may help identify mixed AD/LATE pathology and support clinical trial enrichment. Highlights: Quartiles of HVs stratify CI individuals. Approach distinguishes suspected AD+sLATE–, AD–sLATE+, and AD+sLATE+ subgroups. The method is simple, scalable, and requires no complex modeling or biomarker panels. It enables practical identification of mixed pathology in clinical settings. It supports trial enrichment by excluding or targeting mixed pathology cases.
- Open Access
Enrichment of patients with concomitant LATE on the Alzheimer’s disease continuum using hippocampal volume
Introduction Clinical overlap between Alzheimer’s disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE), combined with absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut-off and examined associated atrophy and cognitive profiles. Methods We studied cognitively impaired ADNI participants with T1-MRI and amyloid- and tau-PET. Participants were classified into suspected (s) AD+sLATE-, AD-sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole-brain atrophy patterns and cognitive profiles were compared cross-sectionally and longitudinally. Classification was validated in an autopsy cohort. Results AD+sLATE+ showed greater anterior hippocampal and amygdala atrophy than AD+sLATE-. AD-sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. Discussion A simple HV quartile cut-off may help identify mixed AD/LATE pathology and support clinical trial enrichment.
Open AccessEnrichment of patients with concomitant LATE on the Alzheimer’s disease continuum using hippocampal volume
Introduction Clinical overlap between Alzheimer’s disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE), combined with absence of validated in vivo biomarkers, complicates identification of mixed AD/LATE pathology. We labeled individuals along the AD continuum with suspected concomitant LATE using the lower quartile hippocampal volume (HV) cut-off and examined associated atrophy and cognitive profiles. Methods We studied cognitively impaired ADNI participants with T1-MRI and amyloid- and tau-PET. Participants were classified into suspected (s) AD+sLATE-, AD-sLATE+, or AD+sLATE+ based on amyloid status and HV quartiles. Medial temporal lobe (MTL) and whole-brain atrophy patterns and cognitive profiles were compared cross-sectionally and longitudinally. Classification was validated in an autopsy cohort. Results AD+sLATE+ showed greater anterior hippocampal and amygdala atrophy than AD+sLATE-. AD-sLATE+ and AD+sLATE+ showed greater anterior MTL atrophy and worse memory and language performance. AD+sLATE+ also exhibited faster cognitive decline. Discussion A simple HV quartile cut-off may help identify mixed AD/LATE pathology and support clinical trial enrichment.
- Open Access
Concordance between amyloid-PET quantification and real-world visual reads: results from IDEAS
Amyloid-PET detects fibrillar β-amyloid deposits, a defining feature of Alzheimer’s disease. This technology has been used in research for over 20 years, and is now used in clinical practice to guide patient diagnosis and management. However, the real-world use of amyloid-PET may differ from research settings due to less standardized acquisition protocols, less experienced visual readers, and patients with more comorbidities, potentially compromising test accuracy. We evaluated the performance of amyloid-PET as used in a real-world clinical setting utilizing data collected via the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study. The study collected clinical amyloid-PET scans of older adults with cognitive decline acquired in 294 imaging facilities using three FDA-approved radiotracers. We centrally processed these scans using a PET-only processing pipeline and derived summary quantification of cerebral radiotracer retention measured on the Centiloid scale. We applied an a priori autopsy-based threshold of 24.4 Centiloids to quantitatively define scan positivity and compared this quantitative classification with binary visual reads performed by local radiologists or nuclear medicine physicians. 10,350/10,774 scans (96%) passed quality control and were successfully quantified. Median patient age was 75 (interquartile range 71, 80) years, 51% were females, 87% self-identified as White, 63% had mild cognitive impairment (vs. 37% with dementia), and 61% of scans were visually positive based on local reads. Centiloid values were higher in visually positive scans (median=74 [46, 99]) compared to scans locally read as negative (−2 [−13, 12]; p18 F-flutemetamol and 18 F-florbetaben (compared to 18 F-florbetapir) were associated with higher visual-quantitative concordance. In conclusion, local visual reads showed high concordance with central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET as used in the real world and the use of quantification in clinical settings.
Open AccessConcordance between amyloid-PET quantification and real-world visual reads: results from IDEAS
Amyloid-PET detects fibrillar β-amyloid deposits, a defining feature of Alzheimer’s disease. This technology has been used in research for over 20 years, and is now used in clinical practice to guide patient diagnosis and management. However, the real-world use of amyloid-PET may differ from research settings due to less standardized acquisition protocols, less experienced visual readers, and patients with more comorbidities, potentially compromising test accuracy. We evaluated the performance of amyloid-PET as used in a real-world clinical setting utilizing data collected via the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study. The study collected clinical amyloid-PET scans of older adults with cognitive decline acquired in 294 imaging facilities using three FDA-approved radiotracers. We centrally processed these scans using a PET-only processing pipeline and derived summary quantification of cerebral radiotracer retention measured on the Centiloid scale. We applied an a priori autopsy-based threshold of 24.4 Centiloids to quantitatively define scan positivity and compared this quantitative classification with binary visual reads performed by local radiologists or nuclear medicine physicians. 10,350/10,774 scans (96%) passed quality control and were successfully quantified. Median patient age was 75 (interquartile range 71, 80) years, 51% were females, 87% self-identified as White, 63% had mild cognitive impairment (vs. 37% with dementia), and 61% of scans were visually positive based on local reads. Centiloid values were higher in visually positive scans (median=74 [46, 99]) compared to scans locally read as negative (−2 [−13, 12]; p18 F-flutemetamol and 18 F-florbetaben (compared to 18 F-florbetapir) were associated with higher visual-quantitative concordance. In conclusion, local visual reads showed high concordance with central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET as used in the real world and the use of quantification in clinical settings.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Association of FDG‐PET with co‐pathologies in autopsy‐proven AD
Background: The presence of multiple pathologies is the rule and not the exception in Alzheimer’s disease (AD). The goal of this study was to assess whether 18F fluorodeoxyglucose (FDG) PET can provide information about the presence of non‐AD pathologies in autopsy‐proven AD patients.Method: Our cohort included 55 patients with antemortem FDG‐PET and autopsy‐proven intermediate/high ADNC from the UCSF Neurodegenerative Diseases Brain Bank. All patients underwent FDG‐PET. Standardized uptake value ratio (SUVR) images were computed using the pons as reference region. W‐maps (adjusted Z‐score maps) were created, comparing each patient to a group of 187 controls (age range: 20‐96, 40% males). Voxel‐wise correlations were computed to verify the unique contribution of each neuropathology to cerebral hypometabolism, while controlling for age, sex, time between FDG‐PET scan and death, scanner type, Thal and Braak staging, and the presence of all other co‐pathologies. Associations between SUVR values in specific region of interests (ROIs) were also assessed. The ROIs included were the following: Landau AD ROI for AD pathology, Cingulate Island Sign (CIS) for Lewy body disease, Inferior/Medial Temporal Lobe (IMT) and IMT/Frontal Supraorbital (IMT/FSO) ratios for limbic‐predominant age‐related TDP43 encephalopathy neuropathologic change (LATE‐NC).Result: Mean age was 63.8 ± 10.5, mean time between FDG and death was 6.2 ± 2.8, and mean MMSE was 21.1 ± 7.1 at the time of PET (Table 1). Group averaged W‐map showed the typical temporo‐parietal AD pattern; hypometabolism in these regions was associated with higher Thal phase and Braak stage (Figure 1). Lewy body disease (LBD), argyrophilic grain disease (AGD), aging‐related tau astrogliopathy (ARTAG), cerebral amyloid angiopathy (CAA) and vascular brain injury (VBI) were associated with hypometabolism in small discrete regional clusters (Figure 2). The Landau AD ROI was associated with both Thal (rs = ‐0.325, p = .015) and Braak stages (rs = ‐0.447, p<.001). The CIS sign was not associated with the presence of LBD (t(53) = 1.01, p = 0.319). Both the IMT (t(53) = ‐2.25, p = .028) and IMT/FSO (t(53) = ‐3.40, p = .001) ratios were associated with the presence of LATE‐NC.Conclusion: Co‐pathologies make a relatively small contribution to hypometabolism in patients with intermediate‐high ADNC. Novel biomarkers are needed for precise detection of co‐pathologies.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessAssociation of FDG‐PET with co‐pathologies in autopsy‐proven AD
Background: The presence of multiple pathologies is the rule and not the exception in Alzheimer’s disease (AD). The goal of this study was to assess whether 18F fluorodeoxyglucose (FDG) PET can provide information about the presence of non‐AD pathologies in autopsy‐proven AD patients.Method: Our cohort included 55 patients with antemortem FDG‐PET and autopsy‐proven intermediate/high ADNC from the UCSF Neurodegenerative Diseases Brain Bank. All patients underwent FDG‐PET. Standardized uptake value ratio (SUVR) images were computed using the pons as reference region. W‐maps (adjusted Z‐score maps) were created, comparing each patient to a group of 187 controls (age range: 20‐96, 40% males). Voxel‐wise correlations were computed to verify the unique contribution of each neuropathology to cerebral hypometabolism, while controlling for age, sex, time between FDG‐PET scan and death, scanner type, Thal and Braak staging, and the presence of all other co‐pathologies. Associations between SUVR values in specific region of interests (ROIs) were also assessed. The ROIs included were the following: Landau AD ROI for AD pathology, Cingulate Island Sign (CIS) for Lewy body disease, Inferior/Medial Temporal Lobe (IMT) and IMT/Frontal Supraorbital (IMT/FSO) ratios for limbic‐predominant age‐related TDP43 encephalopathy neuropathologic change (LATE‐NC).Result: Mean age was 63.8 ± 10.5, mean time between FDG and death was 6.2 ± 2.8, and mean MMSE was 21.1 ± 7.1 at the time of PET (Table 1). Group averaged W‐map showed the typical temporo‐parietal AD pattern; hypometabolism in these regions was associated with higher Thal phase and Braak stage (Figure 1). Lewy body disease (LBD), argyrophilic grain disease (AGD), aging‐related tau astrogliopathy (ARTAG), cerebral amyloid angiopathy (CAA) and vascular brain injury (VBI) were associated with hypometabolism in small discrete regional clusters (Figure 2). The Landau AD ROI was associated with both Thal (rs = ‐0.325, p = .015) and Braak stages (rs = ‐0.447, p<.001). The CIS sign was not associated with the presence of LBD (t(53) = 1.01, p = 0.319). Both the IMT (t(53) = ‐2.25, p = .028) and IMT/FSO (t(53) = ‐3.40, p = .001) ratios were associated with the presence of LATE‐NC.Conclusion: Co‐pathologies make a relatively small contribution to hypometabolism in patients with intermediate‐high ADNC. Novel biomarkers are needed for precise detection of co‐pathologies.
- Open Access
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Association of FDG‐PET with co‐pathologies in autopsy‐proven AD
Background: The presence of multiple pathologies is the rule and not the exception in Alzheimer’s disease (AD). The goal of this study was to assess whether 18F fluorodeoxyglucose (FDG) PET can provide information about the presence of non‐AD pathologies in autopsy‐proven AD patients.Method: Our cohort included 55 patients with antemortem FDG‐PET and autopsy‐proven intermediate/high ADNC from the UCSF Neurodegenerative Diseases Brain Bank. All patients underwent FDG‐PET. Standardized uptake value ratio (SUVR) images were computed using the pons as reference region. W‐maps (adjusted Z‐score maps) were created, comparing each patient to a group of 187 controls (age range: 20‐96, 40% males). Voxel‐wise correlations were computed to verify the unique contribution of each neuropathology to cerebral hypometabolism, while controlling for age, sex, time between FDG‐PET scan and death, scanner type, Thal and Braak staging, and the presence of all other co‐pathologies. Associations between SUVR values in specific region of interests (ROIs) were also assessed. The ROIs included were the following: Landau AD ROI for AD pathology, Cingulate Island Sign (CIS) for Lewy body disease, Inferior/Medial Temporal Lobe (IMT) and IMT/Frontal Supraorbital (IMT/FSO) ratios for limbic‐predominant age‐related TDP43 encephalopathy neuropathologic change (LATE‐NC).Result: Mean age was 63.8 ± 10.5, mean time between FDG and death was 6.2 ± 2.8, and mean MMSE was 21.1 ± 7.1 at the time of PET (Table 1). Group averaged W‐map showed the typical temporo‐parietal AD pattern; hypometabolism in these regions was associated with higher Thal phase and Braak stage (Figure 1). Lewy body disease (LBD), argyrophilic grain disease (AGD), aging‐related tau astrogliopathy (ARTAG), cerebral amyloid angiopathy (CAA) and vascular brain injury (VBI) were associated with hypometabolism in small discrete regional clusters (Figure 2). The Landau AD ROI was associated with both Thal (rs = ‐0.325, p = .015) and Braak stages (rs = ‐0.447, p<.001). The CIS sign was not associated with the presence of LBD (t(53) = 1.01, p = 0.319). Both the IMT (t(53) = ‐2.25, p = .028) and IMT/FSO (t(53) = ‐3.40, p = .001) ratios were associated with the presence of LATE‐NC.Conclusion: Co‐pathologies make a relatively small contribution to hypometabolism in patients with intermediate‐high ADNC. Novel biomarkers are needed for precise detection of co‐pathologies.
- 24 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S10)
Open AccessAssociation of FDG‐PET with co‐pathologies in autopsy‐proven AD
Background: The presence of multiple pathologies is the rule and not the exception in Alzheimer’s disease (AD). The goal of this study was to assess whether 18F fluorodeoxyglucose (FDG) PET can provide information about the presence of non‐AD pathologies in autopsy‐proven AD patients.Method: Our cohort included 55 patients with antemortem FDG‐PET and autopsy‐proven intermediate/high ADNC from the UCSF Neurodegenerative Diseases Brain Bank. All patients underwent FDG‐PET. Standardized uptake value ratio (SUVR) images were computed using the pons as reference region. W‐maps (adjusted Z‐score maps) were created, comparing each patient to a group of 187 controls (age range: 20‐96, 40% males). Voxel‐wise correlations were computed to verify the unique contribution of each neuropathology to cerebral hypometabolism, while controlling for age, sex, time between FDG‐PET scan and death, scanner type, Thal and Braak staging, and the presence of all other co‐pathologies. Associations between SUVR values in specific region of interests (ROIs) were also assessed. The ROIs included were the following: Landau AD ROI for AD pathology, Cingulate Island Sign (CIS) for Lewy body disease, Inferior/Medial Temporal Lobe (IMT) and IMT/Frontal Supraorbital (IMT/FSO) ratios for limbic‐predominant age‐related TDP43 encephalopathy neuropathologic change (LATE‐NC).Result: Mean age was 63.8 ± 10.5, mean time between FDG and death was 6.2 ± 2.8, and mean MMSE was 21.1 ± 7.1 at the time of PET (Table 1). Group averaged W‐map showed the typical temporo‐parietal AD pattern; hypometabolism in these regions was associated with higher Thal phase and Braak stage (Figure 1). Lewy body disease (LBD), argyrophilic grain disease (AGD), aging‐related tau astrogliopathy (ARTAG), cerebral amyloid angiopathy (CAA) and vascular brain injury (VBI) were associated with hypometabolism in small discrete regional clusters (Figure 2). The Landau AD ROI was associated with both Thal (rs = ‐0.325, p = .015) and Braak stages (rs = ‐0.447, p<.001). The CIS sign was not associated with the presence of LBD (t(53) = 1.01, p = 0.319). Both the IMT (t(53) = ‐2.25, p = .028) and IMT/FSO (t(53) = ‐3.40, p = .001) ratios were associated with the presence of LATE‐NC.Conclusion: Co‐pathologies make a relatively small contribution to hypometabolism in patients with intermediate‐high ADNC. Novel biomarkers are needed for precise detection of co‐pathologies.
- Open Access
- 1 April 2021
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (2) , 728-752
Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology
- 1 April 2021
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (2) , 728-752
Open AccessNeuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology